EXEL EXELIXIS, INC.

Nasdaq exelixis.com


$ 40.28 $ 0.74 (1.87 %)    

Wednesday, 15-Oct-2025 11:28:33 EDT
QQQ $ 605.67 $ 1.86 (0.31 %)
DIA $ 465.42 $ 0.78 (0.17 %)
SPY $ 668.09 $ 1.31 (0.2 %)
TLT $ 91.21 $ 0.25 (0.27 %)
GLD $ 386.67 $ 0.74 (0.19 %)
$ 39.51
$ 39.61
$ 40.24 x 30
$ 40.28 x 11
$ 39.61 - $ 40.54
$ 26.06 - $ 49.62
3,135,220
na
10.64B
$ 0.68
$ 17.66
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-28-2025 07-04-2025 10-Q
2 05-13-2025 04-04-2025 10-Q
3 02-11-2025 01-03-2025 10-K
4 10-29-2024 09-27-2024 10-Q
5 08-06-2024 06-28-2024 10-Q
6 04-30-2024 03-29-2024 10-Q
7 02-06-2024 12-29-2023 10-K
8 11-01-2023 09-29-2023 10-Q
9 08-01-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 02-07-2023 12-30-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-09-2022 07-01-2022 10-Q
14 05-10-2022 04-01-2022 10-Q
15 02-18-2022 12-31-2021 10-K
16 11-02-2021 10-01-2021 10-Q
17 08-05-2021 07-02-2021 10-Q
18 05-06-2021 04-02-2021 10-Q
19 02-11-2021 01-01-2021 10-K
20 11-05-2020 10-02-2020 10-Q
21 08-06-2020 07-03-2020 10-Q
22 05-05-2020 04-03-2020 10-Q
23 02-25-2020 01-03-2020 10-K
24 10-30-2019 09-27-2019 10-Q
25 07-31-2019 06-28-2019 10-Q
26 05-01-2019 03-29-2019 10-Q
27 02-22-2019 12-28-2018 10-K
28 11-01-2018 09-28-2018 10-Q
29 08-01-2018 06-29-2018 10-Q
30 05-02-2018 03-30-2018 10-Q
31 02-26-2018 12-29-2017 10-K
32 11-01-2017 09-29-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-01-2017 03-31-2017 10-Q
35 02-27-2017 12-30-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-03-2016 07-01-2016 10-Q
38 05-04-2016 04-01-2016 10-Q
39 02-29-2016 01-01-2016 10-K
40 11-10-2015 10-02-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 morgan-stanley-maintains-overweight-on-exelixis-raises-price-target-to-50

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Overweight and raises the price target from $46 t...

 goldman-sachs-initiates-coverage-on-exelixis-with-buy-rating-announces-price-target-of-47

Goldman Sachs analyst Paul Choi initiates coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and announces Price Target of...

 hc-wainwright--co-maintains-buy-on-exelixis-lowers-price-target-to-46

HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and lowers the price target from $5...

 novo-nordisk-united-parcel-service-and-moderna-are-among-top-10-large-cap-losers-last-week-july-28-august-1-are-the-others-in-your-portfolio

Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts.

 ubs-maintains-neutral-on-exelixis-lowers-price-target-to-38

UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:EXEL) with a Neutral and lowers the price target from $43 to $38.

 amd-rises-to-1-year-highs-crude-eyes-68-whats-moving-markets-tuesday

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced ...

 analyst-surprised-by-exelixis-q2-revenue-miss-delays-stellar-304-readout-halts-stellar-305-phase-3-plans

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shap...

 truist-securities-maintains-buy-on-exelixis-lowers-price-target-to-49

Truist Securities analyst Asthika Goonewardene maintains Exelixis (NASDAQ:EXEL) with a Buy and lowers the price target from ...

 morgan-stanley-maintains-overweight-on-exelixis-lowers-price-target-to-46

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Overweight and lowers the price target from $48 t...

 rbc-capital-maintains-sector-perform-on-exelixis-lowers-price-target-to-45

RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and lowers the price target from ...

 jmp-securities-reiterates-market-outperform-on-exelixis-maintains-50-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Exelixis (NASDAQ:EXEL) with a Market Outperform and maintains $50 price ta...

 guggenheim-reiterates-buy-on-exelixis-maintains-45-price-target

Guggenheim analyst Michael Schmitz reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $45 price target.

 stifel-maintains-hold-on-exelixis-raises-price-target-to-41

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $38 to $41.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION